Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Roche Holding AG: Funding the Genentech Acquisition
Schill, Michael J.; Durick, Brett; Chambers, DrewCaso DARDEN-F-1645-EFinanzasThis case examines the decision by the Swiss pharmaceutical Roche Holding AG (Roche) to offer a record $42 billion bond in February 2009. In light of a pending acquisition of US biotechnology leader Genentech, Roche management planned to sell $32 billion in bonds at various maturities from 1 year to 30 years and in three different currencies (US dollar, euro, and British pound). In a context of substantial uncertainty in both world financial mark...Desde 8,20 €
-
Guna Fibres, Ltd.
Schill, Michael J.; Bruner, Robert F.; Pham, Thien T.Caso DARDEN-F-1687-EFinanzasThe chief executive of a small yarn-production company in India must resolve an unexpected cash shortage. The task for the student is to evaluate the causes of this shortage (using a completed “base-case” forecast given in the case) and assess the usefulness of various possible remedies suggested by managers. The company is unable to liquidate a seasonal working-capital loan for the requisite 30 days each year, a difficulty arising from two class...Desde 8,20 €
-
Carly's Car Clinic
Schill, Michael J.Caso DARDEN-F-2007-EFinanzasThis short fictional case considers an investment decision in a new business concept, Carly's Car Clinic. The investment choice entails two similar stores with correlated outcomes and an option to sequence the opening of one after the other. Student analysis highlights the value of the optionality to delay the opening of one of the stores and then not make the subsequent investment if the outcome on the first one is poor. An instructor should a...Desde 8,20 €
-
Teva Pharmaceuticals: Pricing the 2016 Bond Offering
Schill, Michael J.; Yates, AdamCaso DARDEN-F-2028-EFinanzasThis case examines the July 2016 decision by Israeli pharmaceutical Teva Pharmaceuticals Industries Limited (Teva) to raise USD19.5 billion in cash through a multicurrency bond offering to finance an acquisition that would firmly solidify Teva’s position as the largest generic pharmaceuticals manufacturer in the world. In light of a pending acquisition of Actavis, the generic drug manufacturing arm of Irish-US pharmaceutical Allergen Inc. (Allerg...Desde 8,20 €